Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

Affiliations

• ¹ Sarah Cannon Research Institute, 93 Harley St, Marylebone, London, W1G 6AD, UK. jinfante@tnonc.com.
• ² Tennessee Oncology, PLLC, 250 25th Ave North, Nashville, TN, 37203, USA. jinfante@tnonc.com.
• ³ Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
• ⁴ California PacificMedical Center (Sutterhealth), 475 Brannan Street, Suite 220, San Francisco, CA, 94107, USA.
• ⁵ Sarah Cannon Research Institute, 93 Harley St, Marylebone, London, W1G 6AD, UK.
• ⁶ Tennessee Oncology, PLLC, 250 25th Ave North, Nashville, TN, 37203, USA.
• ⁷ AstraZeneca, 1800 Concord Pike, Wilmington, DE, 19850, USA.
• ⁸ AstraZeneca, Charter Way, Macclesfield, SK10 2NA, UK.
• ⁹ Yale Cancer Center, 55 Park Street, Ste First Floor, New Haven, CT, 06519, USA.